Source:http://linkedlifedata.com/resource/umls/id/C0040879
MSH: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.,CSP: 8-chloro-6-(2-chlorophenyl)-1-methyl- 1,2,4-triazolobenzodiazepine.,NCI: A triazolobenzodiazepinederivative with sedative-hypnotic property. Triazolam interacts directly with a specific site on the gamma-aminobutyric acid (GABA)-A-chloride-ionophore receptor complex located on the neuronal membrane. Binding causes allosteric modification of the receptor and modulation of its affinity for the inhibitory neurotransmitter GABA. This results in enhancement of synaptic actions of GABA and includes an increase in the frequency of chloride channel openings, increased chloride ion conductance, membrane hyperpolarization and ultimately synaptic inhibition and decreased